Synthesis of ZnO nanocrystals by subsequent implantation of Zn and O species

We report the preparation of ZnO nanocrystals embedded in a SiO2 matrix formed using sequential zinc and oxygen ion implantations. The optical absorption spectra and photoemission spectra of zinc implanted and zinc/oxygen coimplanted silica show that the first zinc implantation produces zinc clusters and that the subsequent oxygen implantation following the zinc implantation rearranges the distribution of zinc and oxygen ions at an atomic level. While thermal annealing of Zn only implanted silica leads to the formation of Zn nanocrystals, thermal annealing of zinc/oxygen coimplanted silica promotes the growth of ZnO nanocrystals. The absorption and photoluminescence spectra show that ZnO nanocrystals form in an amorphous SiO2 matrix and that their systematic change as a function of annealing temperature corresponds to the typical correlation between the increase of particle size and a redshift in near-band-edge emission.Peer reviewedMechanical and Aerospace Engineerin

Parameter uncertainty and sensitivity in a liquid-effluent dose model

Radioactive materials which are released into streams on the Savannah River Site (SRS) eventually flow into the Savannah River. Tritium, 90 Sr, 137 Cs, and 239 Pu account for the majority of the radiation dose received by users of the Savannah River. This paper focuses on the dose uncertainties originating from variability in parameters describing the transport and uptake of these nuclides. Parameter sensitivity has also been determined for each liquid pathway exposure model. The models used here to estimate radiation dose to an exposed individual provide a range of possible dose estimates that span approximately one order of magnitude. A pathway analysis reveals that aquatic food and water consumption account for more than 95% of the total dose to an individual.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/42692/1/10661_2004_Article_BF00547126.pd

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

INTRODUCTION: Amyloid beta (Aβ) oligomers are one of the most toxic structural forms of the Aβ protein and are hypothesized to cause synaptotoxicity and memory failure as they build up in Alzheimer's disease (AD) patients' brain tissue. We previously demonstrated that antagonists of the sigma-2 receptor complex effectively block Aβ oligomer toxicity. CT1812 is an orally bioavailable, brain penetrant small molecule antagonist of the sigma-2 receptor complex that appears safe and well tolerated in healthy elderly volunteers. We tested CT1812's effect on Aβ oligomer pathobiology in preclinical AD models and evaluated CT1812's impact on cerebrospinal fluid (CSF) protein biomarkers in mild to moderate AD patients in a clinical trial (ClinicalTrials.gov NCT02907567). METHODS: Experiments were performed to measure the impact of CT1812 versus vehicle on Aβ oligomer binding to synapses in vitro, to human AD patient post mortem brain tissue ex vivo, and in living APPSwe /PS1dE9 transgenic mice in vivo. Additional experiments were performed to measure the impact of CT1812 versus vehicle on Aβ oligomer-induced deficits in membrane trafficking rate, synapse number, and protein expression in mature hippocampal/cortical neurons in vitro. The impact of CT1812 on cognitive function was measured in transgenic Thy1 huAPPSwe/Lnd+ and wild-type littermates. A multicenter, double-blind, placebo-controlled parallel group trial was performed to evaluate the safety, tolerability, and impact on protein biomarker expression of CT1812 or placebo given once daily for 28 days to AD patients (Mini-Mental State Examination 18-26). CSF protein expression was measured by liquid chromatography with tandem mass spectrometry or enzyme-linked immunosorbent assay in samples drawn prior to dosing (Day 0) and at end of dosing (Day 28) and compared within each patient and between pooled treated versus placebo-treated dosing groups. RESULTS: CT1812 significantly and dose-dependently displaced Aβ oligomers bound to synaptic receptors in three independent preclinical models of AD, facilitated oligomer clearance into the CSF, increased synaptic number and protein expression in neurons, and improved cognitive performance in transgenic mice. CT1812 significantly increased CSF concentrations of Aβ oligomers in AD patient CSF, reduced concentrations of synaptic proteins and phosphorylated tau fragments, and reversed expression of many AD-related proteins dysregulated in CSF. DISCUSSION: These preclinical studies demonstrate the novel disease-modifying mechanism of action of CT1812 against AD and Aβ oligomers. The clinical results are consistent with preclinical data and provide evidence of target engagement and impact on fundamental disease-related signaling pathways in AD patients, supporting further development of CT1812

Serum amyloid A primes microglia for ATP-dependent interleukin-1\u3b2 release

Acute-phase response is a systemic reaction to environmental/inflammatory insults and involves production of acute-phase proteins, including serum amyloid A (SAA). Interleukin-1\u3b2 (IL-1\u3b2), a master regulator of neuroinflammation produced by activated inflammatory cells of the myeloid lineage, in particular microglia, plays a key role in the pathogenesis of acute and chronic diseases of the peripheral nervous system and CNS. IL-1\u3b2 release is promoted by ATP acting at the purinergic P2X7 receptor (P2X7R) in cells primed with toll-like receptor (TLR) ligands

Radioecological studies related to the BANEBERRY event

On December 18, 1970, at 7:30 a.m., PST, a venting occurred at the Nevada Test Site in conjunction with the Baneberry test. The Lawrence Radiation Laboratory (LRL) Bio-Medical Research Division and the University of Utah responded to this event by activating their jointly operated air-sampling network and by gathering forage, milk, and animal samples. These data are used to calculate the dose to humans from inhalation, submersion, and food-chain contamination; food-chain contamination calculations are limited to the cow-milk pathway, but included bovine inhalation. The question of food-chain contamination is explored under both the actual situation that dairy cows were fed stored feed and under the hypothetical situation that dairy cows were fed fresh feed. Our results show that {sup 131}I was the significant radionuclide emitted by the event and that the strongest dose was received by the thyroid glands of both foraging animals and humans. The integrated concentrations of {sup 131}I were higher in the northern part of Utah; the maximum value of 1100 pCi h m{sup {minus}3} was recorded at Draper (near Salt Lake City). For conservative results, we calculated the dose to a child rather than an adult. For the actual conditions following the venting, we estimate on the basis of measurements of baled hay and or milk that the dose to an infant's thyroid via the cow-milk pathway was between 0.0065 and 0.012 rad at Draper. If cows had been continuously on fresh pasture, we estimate that the dose to the infant thyroid for the same integrated air concentration would have been 1.3 rad for dry deposition and up to 100 rad for wet deposition. 24 refs., 3 figs., 13 tabs

AMS 3.0: prediction of post-translational modifications

<p>Abstract</p> <p>Background</p> <p>We present here the recent update of AMS algorithm for identification of post-translational modification (PTM) sites in proteins based only on sequence information, using artificial neural network (ANN) method. The query protein sequence is dissected into overlapping short sequence segments. Ten different physicochemical features describe each amino acid; therefore nine residues long segment is represented as a point in a 90 dimensional space. The database of sequence segments with confirmed by experiments post-translational modification sites are used for training a set of ANNs.</p> <p>Results</p> <p>The efficiency of the classification for each type of modification and the prediction power of the method is estimated here using recall (sensitivity), precision values, the area under receiver operating characteristic (ROC) curves and leave-one-out tests (LOOCV). The significant differences in the performance for differently optimized neural networks are observed, yet the AMS 3.0 tool integrates those heterogeneous classification schemes into the single consensus scheme, and it is able to boost the precision and recall values independent of a PTM type in comparison with the currently available state-of-the art methods.</p> <p>Conclusions</p> <p>The standalone version of AMS 3.0 presents an efficient way to indentify post-translational modifications for whole proteomes. The training datasets, precompiled binaries for AMS 3.0 tool and the source code are available at <url>http://code.google.com/p/automotifserver</url> under the Apache 2.0 license scheme.</p

Expression and Differential Responsiveness of Central Nervous System Glial Cell Populations to the Acute Phase Protein Serum Amyloid A

Acute-phase response is a systemic reaction to environmental/inflammatory insults and involves hepatic production of acute-phase proteins, including serum amyloid A (SAA). Extrahepatically, SAA immunoreactivity is found in axonal myelin sheaths of cortex in Alzheimer's disease and multiple sclerosis (MS), although its cellular origin is unclear. We examined the responses of cultured rat cortical astrocytes, microglia and oligodendrocyte precursor cells (OPCs) to master pro-inflammatory cytokine tumour necrosis factor (TNF)-\u3b1 and lipopolysaccaride (LPS). TNF-\u3b1 time-dependently increased Saa1 (but not Saa3) mRNA expression in purified microglia, enriched astrocytes, and OPCs (as did LPS for microglia and astrocytes). Astrocytes depleted of microglia were markedly less responsive to TNF-\u3b1 and LPS, even after re-addition of microglia. Microglia and enriched astrocytes showed complementary Saa1 expression profiles following TNF-\u3b1 or LPS challenge, being higher in microglia with TNF-\u3b1 and higher in astrocytes with LPS. Recombinant human apo-SAA stimulated production of both inflammatory mediators and its own mRNA in microglia and enriched, but not microglia-depleted astrocytes. Co-ultramicronized palmitoylethanolamide/luteolin, an established anti-inflammatory/neuroprotective agent, reduced Saa1 expression in OPCs subjected to TNF-\u3b1 treatment. These last data, together with past findings suggest that co-ultramicronized palmitoylethanolamide/luteolin may be a novel approach in the treatment of inflammatory demyelinating disorders like MS

BRCA2 gene mutations in families with aggregations of breast and stomach cancers

Stomach cancer ranks second to lung cancer in the global cancer burden. It is estimated that 25% of families meeting the criteria for hereditary diffuse gastric carcinoma (HDCG) will have germline mutations in the E-cadherin gene. Evidence suggests that stomach cancer might also be a malignant manifestation of other inherited predispositions to disease. Recently, it has been reported that the incidence of stomach cancer is significantly increased in BRCA2 gene mutation carriers. We analysed by direct sequencing the BRCA2 gene in 29 breast cancer patients derived from 29 families with an aggregation of at least one female breast cancer diagnosed before the age of 50 years and one male stomach cancer diagnosed before the age of 55 years. In all but one of these families at least one additional relative was also affected by a malignant tumour. We identified three frameshift mutations and three sequence variants – potentially missense mutations, in six unrelated patients representing 20.7% (six out of 29) of the families investigated. Our results confirm that BRCA2 gene mutations are also associated with familial aggregations of not only breast but also of stomach cancer. In comparison to the number of cancers expected in the study population compared to the general population there is an over-representation of several cancers with significant confidence intervals to suggest that the associations are real and not a selection artefact